Alyeska Investment Group
BLCM

Alyeska Investment Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Alyeska Investment Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4,909
Closed -$1.13M – 604
2014
Q4 		$1.13M Buy
+4,909
New +$1.05M 0.02% 387

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Alyeska Investment Group's BLCM Position: Q1 2015 in Review

Alyeska Investment Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2015, closing a stake of 4,909 shares — an estimated $1.13M sold.

Alyeska Investment Group first reported a position in BLCM in Q4 2014 and held it in 1 quarter. The position peaked at $1.13M in Q4 2014. 71 funds tracked by Wall St. Rank hold BLCM as of Q1 2015.

  • Alyeska Investment Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 4,909 Bellicum Pharmaceuticals, Inc. shares in Q1 2015, an estimated $1.13M.
  • Alyeska Investment Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 1 quarter.
  • Alyeska Investment Group's Bellicum Pharmaceuticals, Inc. position peaked at $1.13M in Q4 2014.
  • 71 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2015.

Based on Alyeska Investment Group's 13F filing for Q1 2015, filed 15 May 2015.